Wockhardt's Q2 FY27 results show a 22% profit rise despite a 26% revenue fall. The divergence stems from strong biotech growth and a standalone tax benefit, masking the impact of pre-launch costs for its novel antibiotic Zaynich.
For Wockhardt, the September quarter was a story of two realities. The headline figures show a company that made more money on far less sales, a paradox explained by a booming biotech division and a one-time accounting benefit. Yet beneath that, significant investment in a future blockbuster antibiotic is already shaping the bottom line.
Revenue fell sharply to ₹580 crore, down 26% from a year ago and 38% from the previous quarter. Profit, however, rose 22% year-on-year to ₹100 crore. This pushed the net profit margin to 17.2%, a significant 670 basis-point improvement from Q2 FY26.
Revenue & profit
Revenue (₹ Cr)
Profit (₹ Cr)
Revenue (₹ Cr), Q2 FY26: 782
Revenue (₹ Cr), Q3 FY26: 888
Revenue (₹ Cr), Q4 FY26: 965
Revenue (₹ Cr), Q1 FY27: 929
Revenue (₹ Cr), Q2 FY27: 580
Profit (₹ Cr), Q2 FY26: 82
Profit (₹ Cr), Q3 FY26: 61
Profit (₹ Cr), Q4 FY26: 164
Profit (₹ Cr), Q1 FY27: 107
Profit (₹ Cr), Q2 FY27: 100
Revenue (₹ Cr)
Revenue (₹ Cr), Q2 FY26: 782
Revenue (₹ Cr), Q3 FY26: 888
Revenue (₹ Cr), Q4 FY26: 965
Revenue (₹ Cr), Q1 FY27: 929
Revenue (₹ Cr), Q2 FY27: 580
Profit (₹ Cr)
Profit (₹ Cr), Q2 FY26: 82
Profit (₹ Cr), Q3 FY26: 61
Profit (₹ Cr), Q4 FY26: 164
Profit (₹ Cr), Q1 FY27: 107
Profit (₹ Cr), Q2 FY27: 100
Net Profit Margin (%)
Net Profit Margin (%), Q2 FY26: 10.5
Net Profit Margin (%), Q3 FY26: 6.9
Net Profit Margin (%), Q4 FY26: 17.0
Net Profit Margin (%), Q1 FY27: 11.5
Net Profit Margin (%), Q2 FY27: 17.2
Metric
CurrentQ2 FY27
PreviousQ1 FY27
Same quarter LYQ2 FY26
Revenue (₹ Cr)
580YoY -26%
929
782
Profit (₹ Cr)
100YoY +22%
107
82
Net Profit Margin (%)
17.2YoY +64%
11.5
10.5
The biotech engine and the standalone boost
The revenue decline is partly due to the nature of the reported figures. The analysis is based on standalone numbers, which The Economic Times and Moneycontrol reported were ₹580 crore. In contrast, the company's consolidated revenue was up 24% year-on-year to ₹969 crore, driven by a 68% surge in its biotechnology business.
This biotech growth, fueled by demand in emerging markets, was the quarter's operational highlight. The profit increase, however, was significantly aided by a standalone tax benefit. According to Investywise, the standalone result showed a profit before tax and exceptional items of ₹100 crore, with tax expenses recorded at zero.
Live Chart
· WOCKPHARMA
(BSE)
ISIN: INE049B01025
Investing in the antibiotic future
The underlying operational story is one of investment. Wockhardt incurred ₹36 crore in pre-launch expenses for Zaynich, its novel antibiotic recently approved in the US and India. Moneycontrol reported that excluding this cost, the company's consolidated EBITDA would have been ₹201 crore, representing a 26% year-on-year increase.
These costs are a deliberate drag on current profits to fund a future revenue stream. Management expects the Zaynich business to run at a slight loss for 12 to 18 months post-launch before breaking even, with a global peak sales target of $1.5–2 billion.
A stable foundation for the spend
The company's financial position provides room for this investment. The standalone cash flow statement for the half-year showed a net cash inflow of ₹242 crore from operations, according to Investywise. The debt-to-equity ratio stands at a manageable 0.45, and interest coverage is adequate at 2.12 times.
Key Points
Profit grew 22% year-on-year to ₹100 crore despite a 26% drop in standalone revenue, aided by a tax benefit.
Consolidated business health was stronger, with revenue up 24% driven by 68% growth in the biotechnology division.
Pre-launch expenses of ₹36 crore for the novel antibiotic Zaynich weighed on reported margins, representing investment for future growth.
The company maintains a stable financial base with positive operating cash flow to support its launch investments.
“
Hexa Perspective
Wockhardt's quarter underscores its transition. The core generics and insulin businesses are generating the cash, evident in the strong biotech performance and operating cash flow. This funds the ambitious, but costly, rollout of its novel antibiotic portfolio.
The valuation at a P/E of 74.4, a 95% premium to the industry, prices in the success of Zaynich and its pipeline. Investors are essentially paying for the future hockey-stick growth, accepting near-term margin pressure from launch costs. The next few quarters will be about tracking the early commercial signals for Zaynich against the continued strength of the funding biotech engine.
Talk to a HexaWealth advisor, or sync your mutual fund data for insights tailored to your holdings.
Frequently asked questions
What were Wockhardt's Q2 FY27 results?
Wockhardt reported standalone revenue of ₹580 crore and a profit of ₹100 crore for Q2 FY27. Year-on-year, this represents a 26% decline in revenue but a 22% increase in profit. The company's consolidated revenue, however, grew 24% to ₹969 crore, as reported by The Economic Times.
Did Wockhardt's profit rise or fall in Q2 FY27?
Wockhardt's profit rose in Q2 FY27. Standalone profit after tax increased by 22% year-on-year to ₹100 crore. This growth occurred despite a significant drop in reported revenue for the quarter.
What is Wockhardt's revenue for Q2 FY27?
Wockhardt's standalone revenue for Q2 FY27 was ₹580 crore, a 26% decrease from the same quarter last year. It's important to note that the company's consolidated revenue, which includes all subsidiaries, was reported as ₹969 crore by outlets like Moneycontrol, showing 24% growth.
Why did Wockhardt's revenue fall in Q2 FY27?
The reported standalone revenue of ₹580 crore shows a decline, but this is not the full picture. The company's consolidated revenue grew 24%. The standalone figure may reflect different reporting structures, while the consolidated number captures strong growth, particularly from the biotech division which surged 68%.
What drove Wockhardt's profit growth despite lower revenue?
Wockhardt's profit growth was supported by a significant tax benefit on a standalone basis, resulting in zero tax expense for the quarter as per Investywise. Operationally, strong performance in the high-margin biotechnology business, which grew 68%, also helped bolster profitability.
How did Wockhardt's biotech business perform?
Wockhardt's biotechnology business was a standout performer in Q2 FY27. According to The Economic Times, biotech revenue surged 68% year-on-year to ₹252 crore, driven by strong demand and new partnerships in emerging markets like Brazil, Thailand, and Egypt.
What are the pre-launch expenses for Zaynich?
Wockhardt incurred ₹36 crore in pre-launch expenses for its novel antibiotic Zaynich during Q2 FY27, as reported by Moneycontrol. These costs, which weighed on reported margins, are investments ahead of the commercial launch in the US and India.
What is Wockhardt's debt position?
Wockhardt maintains a moderate debt level with a debt-to-equity ratio of 0.45. The company's interest coverage ratio is 2.12, indicating it can service its debt from operating earnings. Standalone cash flow from operations was a positive ₹242 crore for the half-year.
What is the outlook for Wockhardt's novel antibiotic Zaynich?
Management expects the Zaynich business to incur losses for 12-18 months post-launch before breaking even, with a long-term global peak sales target of $1.5–2 billion. The US launch is anticipated around Q1 FY27, with the European Medicines Agency review progressing.
How has Wockhardt's shareholding changed recently?
As of September 2026, promoter holding in Wockhardt stood at 49.3%, largely stable. Domestic institutional investors held 9.0%, a increase of nearly 4 percentage points over the past two years, indicating growing institutional interest according to data from Sector Alpha.